LLY (Lilly) Nilai Agregat Aset

Eli Lilly and Company (LLY) is recognized as a global medical authority due to its development of vital therapeutic solutions. This price chart reflects total assets at 131511.68. The business's success relies on a powerful R&D center and exclusive rights to obesity and diabetes treatments. A steady capital inflow is ensured by high-margin bestsellers, eliminating the likelihood of revenue declines in the foreseeable future.

Aset Agregat Perusahaan lilly.com (LLY): kanggo periode 04.07.2022 - 31.10.2026

Rincian metrik keuangan lan pasar Eli Lilly & Co. (LLY)

- rega saiki lan proyeksi nilai saham:

Bagan kutipan lilly.com|LLY - Prakiraan konsensus analis

- indikator valuasi pasar bisnis:

Nilai pasar Eli Lilly and Co.|LLY - Nilai Perusahaan

- rincian valuasi buku bisnis:

Nilai Buku saben Saham Eli Lilly|LLY - Nilai Buku Perusahaan|Nilai Pasar marang Nilai Buku lilly.com|LLY - Aset Agregat Perusahaan

- indikator beban utang lan likuiditas:

Rasio Total Utang marang Ekuitas Eli Lilly and Company|LLY - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Eli Lilly and Co.|LLY - Gunggung utang perusahaan|Rasio utang marang aset resik Eli Lilly and Co.|LLY - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Eli Lilly|Likuiditas darurat lilly.com

- rincian bathi lan kelipatan pasar:

LLY - Bathi resik perusahaan

Ringkesan analisis perusahaan:lilly.com (LLY)

Eli Lilly and Company (LLY) investments in expanding plants and cold chains directly increase the company's resource base. This metric is calculated inversely via daily return on assets (ROA), reflecting the aggregate of equity and liabilities. The growth of this volume confirms the scale of the business, yet requires a proportional increase in profit to avoid a decline in efficiency. By analyzing the current level of gross assets, an investor assesses the quality of capital management between quarterly reports.

Pesaing langsung